Transcription factor PU.1 is involved in the progression of glioma

Xu,Yuanzhi; Gu,Song; Bi,Yunke; Qi,Xiangqian; Yan,Yujin; Lou,Meiqing

doi:10.3892/ol.2018.7766

Transcription factor PU.1 is involved in the progression of glioma

Authors:
- Yuanzhi Xu
- Song Gu
- Yunke Bi
- Xiangqian Qi
- Yujin Yan
- Meiqing Lou
View Affiliations

Affiliations: Department of Neurosurgery, Shanghai First People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200080, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Neurosurgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang 315020, P.R. China
Published online on: January 10, 2018 https://doi.org/10.3892/ol.2018.7766
Pages: 3753-3759
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is a severe disease of the central nervous system. Although previous studies have identified the important role of the immune response in association with tumor intervention, it is still unknown whether PU.1, a transcription factor known for its role in myeloid differentiation and immune responses, is involved in the progression of glioma. In the present study, we found a significant increase in SPI1, the gene that encodes PU.1, in samples from patients with glioma. Through genotype‑phenotype association analysis several candidate factors that may mediate the role of PU.1 in glioma were identified. To further validate the association between PU.1 and glioma we found that the expression of BTK, a potential target of PU.1, was also upregulated in patients with glioma. We also demonstrated that various biological pathways could be involved in PU.1‑associated glioma by analyzing these potential targets in the Reactome database. These results provide evidence that PU.1 could serve a role in the progress of glioma through its transcriptional targets in multiple signaling pathways. Therefore, in addition to its role in hematopoietic linage development and leukemia, PU.1 appears to be involved in the regulation of glioma and potentially in other malignant cancers.

View Figures

View References

1	Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002. View Article : Google Scholar : PubMed/NCBI
2	Verbiest T, Bouffler S, Nutt SL and Badie C: PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): From molecular mechanism to human AML. Carcinogenesis. 36:413–419. 2015. View Article : Google Scholar : PubMed/NCBI
3	Scott EW, Simon MC, Anastasi J and Singh H: Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 265:1573–1577. 1994. View Article : Google Scholar : PubMed/NCBI
4	McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ and Maki RA: Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 15:5647–5658. 1996.PubMed/NCBI
5	Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S, Arinobu Y, Geary K, Zhang P, Dayaram T, et al: Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood. 106:1590–1600. 2005. View Article : Google Scholar : PubMed/NCBI
6	Torlakovic EE, Bilalovic N, Golouh R, Zidar A and Angel S: Prognostic significance of PU.1 in follicular lymphoma. J Pathol. 209:352–359. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bonadies N, Pabst T and Mueller BU: Heterozygous deletion of the PU.1 locus in human AML. Blood. 115:331–334. 2010. View Article : Google Scholar : PubMed/NCBI
8	Huskova H, Korecka K, Karban J, Vargova J, Vargova K, Dusilkova N, Trneny M and Stopka T: Oncogenic microRNA-155 and its target PU.1: An integrative gene expression study in six of the most prevalent lymphomas. Int J Hematol. 102:441–450. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhou J, Wu J, Li B, Liu D, Yu J, Yan X, Zheng S, Wang J, Zhang L, Zhang L, et al: PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia. 28:1436–1448. 2014. View Article : Google Scholar : PubMed/NCBI
10	de Boer J, Walf-Vorderwülbecke V and Williams O: In focus: MLL-rearranged leukemia. Leukemia. 27:1224–1228. 2013. View Article : Google Scholar : PubMed/NCBI
11	Krivtsov AV and Armstrong SA: MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 7:823–833. 2007. View Article : Google Scholar : PubMed/NCBI
12	Toda Y, Tsukada J, Misago M, Kominato Y, Auron PE and Tanaka Y: Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J Immunol. 168:1984–1991. 2002. View Article : Google Scholar : PubMed/NCBI
13	Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14 Suppl 5:v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
14	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
15	Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
16	Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C and Tavaré S: Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 110:pp. 4009–4014. 2013; View Article : Google Scholar : PubMed/NCBI
17	Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H: The brain tumor microenvironment. Glia. 59:1169–1180. 2011. View Article : Google Scholar : PubMed/NCBI
18	Li W and Graeber MB: The molecular profile of microglia under the influence of glioma. Neuro Oncol. 14:958–978. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hu F, Ku MC, Markovic Da Dzaye OD, Lehnardt S, Synowitz M, Wolf SA and Kettenmann H: Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int J Cancer. 135:2569–2578. 2014. View Article : Google Scholar : PubMed/NCBI
20	Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al: CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 19:1264–1272. 2013. View Article : Google Scholar : PubMed/NCBI
21	Markovic DS, Vinnakota K, van Rooijen N, Kiwit J, Synowitz M, Glass R and Kettenmann H: Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun. 25:624–628. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yuan JX and Munson JM: Quantitative immunohistochemistry of the cellular microenvironment in patient glioblastoma resections. J Vis Exp. 2017. View Article : Google Scholar
23	Cancer Genome Atlas Research Network, . Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
24	Poon H, Quirk C, DeZiel C and Heckerman D: Literome: PubMed-scale genomic knowledge base in the cloud. Bioinformatics. 30:2840–2842. 2014. View Article : Google Scholar : PubMed/NCBI
25	Poon H, Toutanova K and Quirk C: Distant supervision for cancer pathway extraction from text. Pac Symp Biocomput. 1–131. 2015.PubMed/NCBI
26	Müller S, Sideras P, Smith CI and Xanthopoulos KG: Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members. Oncogene. 13:1955–1964. 1996.PubMed/NCBI
27	Starck J, Doubeikovski A, Sarrazin S, Gonnet C, Rao G, Skoultchi A, Godet J, Dusanter-Fourt I and Morle F: Spi-1/PU.1 is a positive regulator of the Fli-1 gene involved in inhibition of erythroid differentiation in friend erythroleukemic cell lines. Mol Cell Biol. 19:121–135. 1999. View Article : Google Scholar : PubMed/NCBI
28	Cinque S, Willems J, Depraetere S, Vermeire L and Joniau M: ‘In vitro’ effect of interleukin-1 beta on human glioma cell lines: Regulation of cell proliferation and IL-6 production. Immunol Lett. 34:267–271. 1992. View Article : Google Scholar : PubMed/NCBI
29	Kaplitt MG, Tjuvajev JG, Leib DA, Berk J, Pettigrew KD, Posner JB, Pfaff DW, Rabkin SD and Blasberg RG: Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol. 19:137–147. 1994. View Article : Google Scholar : PubMed/NCBI
30	Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, Mattot V, Pourtier-Manzanedo A, Pietsch T, Fafeur V and Wernert N: Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes. Int J Oncol. 34:377–389. 2009.PubMed/NCBI
31	Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, Caudy M, Garapati P, Gillespie M, Kamdar MR, et al: The reactome pathway knowledgebase. Nucleic Acids Res. 42(Database issue): D472–D477. 2014. View Article : Google Scholar : PubMed/NCBI
32	Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, Jassal B, Jupe S, Korninger F, McKay S, et al: The reactome pathway knowledgebase. Nucleic Acids Res. 44:D481–D487. 2016. View Article : Google Scholar : PubMed/NCBI
33	Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM and Dinarello CA: Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA. 81:pp. 7907–7911. 1984; View Article : Google Scholar : PubMed/NCBI
34	March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K, et al: Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 315:641–647. 1985. View Article : Google Scholar : PubMed/NCBI
35	Masters SL, Simon A, Aksentijevich I and Kastner DL: Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 27:621–668. 2009. View Article : Google Scholar : PubMed/NCBI
36	Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H and Badie B: Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia. 57:1458–1467. 2009. View Article : Google Scholar : PubMed/NCBI
37	Munkley J, Livermore K, Rajan P and Elliott DJ: RNA splicing and splicing regulator changes in prostate cancer pathology. Hum Genet. 136:1143–1154. 2017. View Article : Google Scholar : PubMed/NCBI
38	Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al: Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Res. 39(Database issue): D691–D697. 2011. View Article : Google Scholar : PubMed/NCBI